These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16735601)

  • 1. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
    Zaitsev S; Danielyan K; Murciano JC; Ganguly K; Krasik T; Taylor RP; Pincus S; Jones S; Cines DB; Muzykantov VR
    Blood; 2006 Sep; 108(6):1895-902. PubMed ID: 16735601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
    Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
    Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
    Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
    Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.
    Danielyan K; Ganguly K; Ding BS; Atochin D; Zaitsev S; Murciano JC; Huang PL; Kasner SE; Cines DB; Muzykantov VR
    Circulation; 2008 Sep; 118(14):1442-9. PubMed ID: 18794394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
    Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Bdeir K; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1022-31. PubMed ID: 19952305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
    Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Marcos-Contreras OA; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
    Blood; 2010 Jun; 115(25):5241-8. PubMed ID: 20410503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
    Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M
    Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
    Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
    Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
    McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
    Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lytic resistance of fibrin containing red blood cells.
    Wohner N; Sótonyi P; Machovich R; Szabó L; Tenekedjiev K; Silva MM; Longstaff C; Kolev K
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2306-13. PubMed ID: 21737785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.
    Zhu Y; Carmeliet P; Fay WP
    Circulation; 1999 Jun; 99(23):3050-5. PubMed ID: 10368124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.